

IvÃ¡n MartÃ-nez-Baz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4026093/publications.pdf>

Version: 2024-02-01

46
papers

1,103
citations

361296

20
h-index

454834

30
g-index

51
all docs

51
docs citations

51
times ranked

1557
citing authors

#	ARTICLE	IF	CITATIONS
1	Transmission of SARS-CoV-2 infection and risk factors in a cohort of close contacts. Postgraduate Medicine, 2022, 134, 230-238.	0.9	14
2	Chronic obstructive pulmonary disease and influenza vaccination effect in preventing outpatient and inpatient influenza cases. Scientific Reports, 2022, 12, 4862.	1.6	5
3	Differences in Transmission between SARS-CoV-2 Alpha (B.1.1.7) and Delta (B.1.617.2) Variants. Microbiology Spectrum, 2022, 10, e0000822.	1.2	17
4	Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021. Eurosurveillance, 2022, 27, .	3.9	16
5	Effectiveness of influenza vaccination in preventing influenza in primary care, Navarre, Spain, 2021/22. Eurosurveillance, 2022, 27, .	3.9	6
6	Absence of association between 2019-20 influenza vaccination and COVID-19: Results of the European I-MOVE-COVID-19 primary care project, March-August 2020. Influenza and Other Respiratory Viruses, 2021, 15, 429-438.	1.5	21
7	Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021. Eurosurveillance, 2021, 26, .	3.9	55
8	Risk Factors of Infection, Hospitalization and Death from SARS-CoV-2: A Population-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 2608.	1.0	42
9	Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care: I-MOVE-COVID-19 project, Europe, December 2020 to May 2021. Eurosurveillance, 2021, 26, .	3.9	38
10	Effect of influenza vaccination in patients with asthma. Cmaj, 2021, 193, E1120-E1128.	0.9	7
11	Simple models to include influenza vaccination history when evaluating the effect of influenza vaccination. Eurosurveillance, 2021, 26, .	3.9	4
12	Product-specific COVID-19 vaccine effectiveness against secondary infection in close contacts, Navarre, Spain, April to August 2021. Eurosurveillance, 2021, 26, .	3.9	48
13	Influenza Vaccination and Risk of SARS-CoV-2 Infection in a Cohort of Health Workers. Vaccines, 2020, 8, 611.	2.1	29
14	Effect of Influenza Vaccination in Preventing Laboratory-Confirmed Influenza Hospitalization in Patients With Diabetes Mellitus. Clinical Infectious Diseases, 2020, 73, 107-114.	2.9	18
15	Effectiveness of the current and prior influenza vaccinations in Northern Spain, 2018-2019. Vaccine, 2020, 38, 1925-1932.	1.7	9
16	Recapture of patients with an incomplete diagnosis of hepatitis C virus infection. Revista Espanola De Enfermedades Digestivas, 2020, 112, 525-531.	0.1	2
17	Health-related quality of life in hepatitis C patients who achieve sustained virological response to direct-acting antivirals: a comparison with the general population. Quality of Life Research, 2019, 28, 1477-1484.	1.5	17
18	Remaining Effect of Influenza Vaccines Received in Prior Seasons. Journal of Infectious Diseases, 2019, 220, 1136-1140.	1.9	12

#	ARTICLE	IF	CITATIONS
19	Survival and clinical events related to end-stage liver disease associated with HCV prior to the era of all oral direct-acting antiviral treatments. <i>Expert Review of Gastroenterology and Hepatology</i> , 2019, 13, 699-708.	1.4	9
20	Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents. <i>Revista Espanola De Enfermedades Digestivas</i> , 2019, 111, 445-452.	0.1	27
21	Comorbidities and cardiovascular risk factors in an aged cohort of HIV-infected patients on antiretroviral treatment in a Spanish hospital in 2016. <i>Postgraduate Medicine</i> , 2018, 130, 317-324.	0.9	10
22	Estimación de la prevalencia de infección diagnosticada y no diagnosticada por el virus de la hepatitis C en Navarra, 2014-2016. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018, 36, 325-331.	0.3	22
23	Respiratory syncytial virus hospitalization in children in northern Spain. <i>PLoS ONE</i> , 2018, 13, e0206474.	1.1	26
24	Progress in the elimination of hepatitis C virus infection: A population-based cohort study in Spain. <i>PLoS ONE</i> , 2018, 13, e0208554.	1.1	16
25	Impact of successful treatment with direct-acting antiviral agents on health-related quality of life in chronic hepatitis C patients. <i>PLoS ONE</i> , 2018, 13, e0205277.	1.1	47
26	Detection of Respiratory Viruses in Deceased Persons, Spain, 2017. <i>Emerging Infectious Diseases</i> , 2018, 24, 1331-1334.	2.0	7
27	Health utilities in Spanish chronic hepatitis C patients treated with direct acting antivirals in real life conditions. <i>Journal of Hepatology</i> , 2018, 68, S543.	1.8	0
28	Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals. <i>Revista Espanola De Enfermedades Digestivas</i> , 2018, 110, 621-628.	0.1	11
29	Comparison of influenza vaccine effectiveness in preventing outpatient and inpatient influenza cases in older adults, northern Spain, 2010/11 to 2015/16. <i>Eurosurveillance</i> , 2018, 23, .	3.9	16
30	Interim effectiveness of trivalent influenza vaccine in a season dominated by lineage mismatched influenza B, northern Spain, 2017/18. <i>Eurosurveillance</i> , 2018, 23, .	3.9	27
31	Effectiveness of seasonal influenza vaccination in community-dwelling elderly people: an individual participant data meta-analysis of test-negative design case-control studies. <i>Lancet Respiratory Medicine</i> , 2017, 5, 200-211.	5.2	53
32	Effect of Repeated Vaccination With the Same Vaccine Component Against 2009 Pandemic Influenza A(H1N1) Virus. <i>Journal of Infectious Diseases</i> , 2017, 215, 847-855.	1.9	35
33	Effect of previous and current vaccination against influenza A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016 in Spain. <i>PLoS ONE</i> , 2017, 12, e0179160.	1.1	18
34	Combined effectiveness of prior and current season influenza vaccination in northern Spain: 2016/17 mid-season analysis. <i>Eurosurveillance</i> , 2017, 22, .	3.9	24
35	Effectiveness of subunit influenza vaccination in the 2014-2015 season and residual effect of split vaccination in previous seasons. <i>Vaccine</i> , 2016, 34, 1350-1357.	1.7	32
36	Effects of previous episodes of influenza and vaccination in preventing laboratory-confirmed influenza in Navarre, Spain, 2013/14 season. <i>Eurosurveillance</i> , 2016, 21, .	3.9	20

#	ARTICLE	IF	CITATIONS
37	Enhanced Estimates of the Influenza Vaccination Effect in Preventing Mortality. <i>Medicine (United)</i> Tj ETQq1 1 0.784314 rgBT /Overlook 0,4 17		
38	Influenza vaccine effectiveness in preventing inpatient and outpatient cases in a season dominated by vaccine-matched influenza B virus. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 1626-1633.	1.4	20
39	Household Transmission of Influenza A(H1N1)pdm09 in the Pandemic and Post-Pandemic Seasons. <i>PLoS ONE</i> , 2014, 9, e108485.	1.1	15
40	Risk factors and effectiveness of preventive measures against influenza in the community. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 177-183.	1.5	25
41	Effectiveness of the trivalent influenza vaccine in Navarre, Spain, 2010â€“2011: a population-based test-negative caseâ€“control study. <i>BMC Public Health</i> , 2013, 13, 191.	1.2	31
42	Trends in influenza vaccine coverage among primary healthcare workers in Spain, 2008â€“2011. <i>Preventive Medicine</i> , 2013, 57, 206-211.	1.6	32
43	Influenza Vaccine Effectiveness in Preventing Outpatient, Inpatient, and Severe Cases of Laboratory-Confirmed Influenza. <i>Clinical Infectious Diseases</i> , 2013, 57, 167-175.	2.9	112
44	Factors associated with continued adherence to influenza vaccination in the elderly. <i>Preventive Medicine</i> , 2012, 55, 246-250.	1.6	33
45	Vaccine effectiveness in preventing influenza hospitalizations in Navarre, Spain, 2010â€“2011: Cohort and caseâ€“control study. <i>Vaccine</i> , 2012, 30, 195-200.	1.7	37
46	Use of Medical Care during Pandemic (H1N1) 2009, Navarre, Spain. <i>Emerging Infectious Diseases</i> , 2011, 17, 1463-6.	2.0	2